Bristol Myers Squibb Co $51.12

up +0.11


30/7/2014 04:03 PM  |  NYSE : BMY  
Industries : Drugs / Drug Manufacturers - Major
Get Trend Analysis Icon Get BMY Trend Analysis - it has underperformed the S&P 500 by 0%

Partner Headlines

  1. Bristol-Myers surprises Street

    IBD
  2. Thursday Morning Earnings Reports

    Benzinga
  3. Stock Futures Steer Higher; Facebook, Skechers Nail Q2 Wins

    IBD
  4. Earnings Scheduled For July 24, 2014

    Benzinga
  5. Facebook, Gilead Headline IBD 50's Top 5 Earnings

    IBD
  6. Benzinga Weekly Preview: Earnings Season Continues With Geopolitical Tensions ...

    Benzinga
  7. UnitedHealth Group Up on Weak Day for the Dow

    GuruFocus
  8. Dow Sets New Intraday High; Citigroup Impresses With Earnings

    Benzinga
  9. Senators Ask Gilead To Explain Sovaldi Pricing

    IBD
  10. Bristol seeks cancer drug nod

    IBD
  11. Bristol-Myers Seeking Nivolumab Approval In Melanoma

    IBD
  12. Japan approves BMY regimen

    IBD
  13. Jazz, Novo Among Medicals Showing Healthy Action

    IBD
  14. Bristol-Myers' All-Oral HCV Therapy Approved In Japan

    IBD
  15. Merck, Gilead Lead Race To Eradicate Hepatitis C

    IBD
  16. Markets Little Changed Ahead Of 4th Of July Break

    Benzinga
  17. Barclays Downgrades Pharmaceutical Sector

    Benzinga
  18. UPDATE: Barclays Downgrades Bristol-Myers, Cuts Price Target By 41%

    Benzinga
  19. Benzinga's Top Downgrades

    Benzinga
  20. Ex-Dividends For July 1, 2014

    Benzinga
  21. Pfizer and others get EU nods

    IBD
  22. Bristol-Myers, Pfizer, Regeneron Drugs Get EU Nods

    IBD
  23. Pfizer, Bristol-Myers Squibb Announce Positive Opinion For Treatments

    Benzinga
  24. US Stock Futures Drop Ahead Of Consumer Sentiment Report

    Benzinga
  25. Bristol-Myers Squibb Receives Positive CHMP Opinion for Daklinza for Treatment ...

    Benzinga
  26. Pharma Sector Stocks To Consider For Sustained Returns

    GuruFocus
  27. Bristol-Myers Stock Up On Nivolumab Trial Success

    IBD
  28. BRISTOL-MYERS SQUIBB

    IBD
  29. UPDATE: Bristol Myers Announces Phase 3 First-Line Study of Nivolumab Stopped ...

    Benzinga
  30. Benzinga's M&A Chatter for Monday June 16, 2014

    Benzinga
  31. Merck Takes The 'Nuc' Option In Hepatitis C Race

    IBD
  32. ASCO Meeting Day 4: Risks And Rewards Of Immunotherapy

    Benzinga
  33. ASCO Meeting Day 3: Do More Treatments Equal A Longer Life?

    Benzinga
  34. Bristol-Myers Offers Two-, Three-Year Survival Data for Nivolumab

    Benzinga
  35. AstraZeneca Woos Shareholders With Promise Of Growth

    IBD
  36. Vanguard Health Care Fund's Top Quarterly Holdings

    GuruFocus
  37. Bristol, Merck Q1 sales soft

    IBD
  38. Bristol, Merck, Sanofi Report Soft Q1 Sales

    IBD
  39. ETF Outlook For Tuesday, April 29, 2014 (IHE, TAN, XRT, SOCL, TWTR)

    Benzinga
  40. UPDATE: Bristol-Myers Posts Higher Q1 Profit

    Benzinga
  41. US Stock Futures Up Ahead Of Earnings, Consumer Confidence Data

    Benzinga
  42. Bristol-Myers Squibb Acquires iPierian for $175M, Potential Milestone Payments ...

    Benzinga
  43. Earnings Scheduled For April 29, 2014

    Benzinga
  44. Stocks To Watch For April 29, 2014

    Benzinga
  45. Pfizer Confirms Pursuit Of AstraZeneca; Stocks Jump

    IBD
  46. Earnings Expectations For The Week Of April 28: Big Oil, Big Pharma And ...

    Benzinga
  47. Benzinga Weekly Preview: Earnings Season Continues As Biotech & Pharmaceutical ...

    Benzinga
  48. Week Ahead: April Jobs Report, FOMC Meeting and Earnings

    FoxBusiness
  49. Pfizer, AstraZeneca Rise On Report Of Merger Talks

    IBD
  50. UPDATE: Bristol-Myers Squibb Submits NDA to US FDA for Fixed-Dose Combo ...

    Benzinga
Trading Center